Male osteoporosis: Neglected and Under Treated Paris, August 17, 2006 The US Food and Drug Administration (FDA) this week approved Actonel® 35mg (risedronate sodium tablets) for treatment to increase bone mass in men with osteoporosis
Sanofi-aventis and Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has approved the supplemental new drug application for the antiplatelet agent PLAVIX® (clopidogrel bisulfate) to reduce the rate of death from any cause and the rate of a combined endpoint of re-infarction, stroke or death in patients with acute ST-segment elevation myocardial infarction.
The consolidated income statement for the first half of 2006 is provided in the appendices. 2006 first-half consolidated net income after minority interests was 2,381 million, compared with 1,087 million for the first half of 2005, after the impact of the accounting treatment of acquisitions (primarily the acquisition of Aventis) and restructuring costs (1,583 million after tax in 2006 and 1,8
Läs Sanofi-Aventis resultat för första hälften av 2006 i bifogade dokument.
Sanofi-aventis responded immediately on Tuesday evening to the call for medical assistance launched by the French Foreign Ministry, to offer support to Lebanon's health authorities and express solidarity with the people of Lebanon.
Måltidsinsulinet Apidra lanseras nu i en engångspenna. Pennan heter OptiSet och är förfylld med Apidra vilket underlättar för patienterna.
EU-kommissionen offentliggjorde igår att läkemedlet Acomplia® (rimonabant) godkänts för försäljning i samtliga EU-länder. Acomplia® är en ny och unik substans som påverkar ett flertal riskfaktorer för hjärtinfarkt och stroke. Sanofi-aventis räknar med att Acomplia® kommer att finnas tillgängligt på den svenska marknaden i början av 2007.
First-in-class CB1 blocker approved for the treatment of obese patients, or overweight patients with associated risk factors, such as type 2 diabetes or dyslipidaemia
Behandling med insulin glargin ger låga blodsockernivåer och färre insulinkänningar med en tredjedel så många injektioner som behandling med insulin lispro. Detta visar Apollo-studien som redovisades på den årliga diabeteskongressen, American Diabetes Associations, ADA, som hölls i Washington D.C. i veckan.
Apollo study shows insulin glargine achieves HbA1c below 7% with less hypoglycemia, 3 times less insulin injections and less self-monitoring than the prandial analog lispro.
Type 2 Diabetes Patients Using a New Insulin Dosing Strategy Achieved a Mean A1C of 6.6% after 24 Weeks of Combination Therapy with Rapid-Acting Apidra® (insulin glulisine [rDNA origin] injection) and 24-hour Lantus® (insulin glargine [rDNA origin] injection).
Paris, France, June 7, 2006 Sanofiaventis announced today key trial results presented at the 42nd annual meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia, regarding the use of Taxotere® (docetaxel) regimens in the treatment of non small cell lung cancer (NSCLC), head and neck cancer and metastatic and adjuvant breast cancer.
Sanofiaventis announced today key results from three studies evaluating Eloxatin® (oxaliplatin injection) in various gastrointestinal tumor types (colorectal, pancreatic and gastric cancers). These results were presented at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia.
Sanofi-aventis announced today that a meta-analysis performed on seven clinical trials in patients with advanced non-small cell lung cancer showed that patients receiving Taxotere® (docetaxel) Injection Concentrate had demonstrated overall survival and less febrile neutropenia than those treated with vinca-alkaloid (vinorelbine or vindesine) regimens.
Sanofi-aventis befinner sig i en expansiv fas med förberedelser inför lansering av ny produkt och många spännande studier i pipeline. Detta resulterar i en omfattande rekrytering.
The Combined General Meeting of Shareholders of sanofi-aventis was held May 31, 2006.
- 430 abstracts from studies involving Taxotere® or Eloxatin® accepted at the meetings scientific sessions -
Lyon, France May 11, 2006 A study published online in The Lancet on May 11 demonstrated that multiple dosage formulations of a candidate H5N1 influenza vaccine developed by sanofi pasteur were well-tolerated and generated an immune response, with and without adjuvant. Of the formulations being tested, an alum-adjuvanted 30 microgram (µg) dosage generated the most substantive immune response (
Paris, France, May 9, 2006 - Sanofi-aventis announced today that PLAVIX® (clopidogrel) has been launched in Japan.
First quarter of 2006: Sales growth of 9.6% on a reported basis and 4.9% on a comparable basis1 52.8% growth in adjusted EPS1 and 19.8% excluding selected items3